Supporting the

Neuroendocrine Cancer Community


Feb 22, 2023

We have been asked by the team at Imperial College London to share the details of the LANTANA study which is recruiting at the moment. This study is being run by Dr Rohini Sharma.
The purpose of this study is to see if a drug called ASTX727 improves the outcome of treatment with Lutathera ( a type of peptide receptor radionuclide therapy) if the patient has low or no uptake of the tracer used in a Gallium PET scan.
Please note that certain examinations and tests, which we may refer to as screening tests, are required to help your study doctor determine whether you are eligible for this study. The screening period of the study can take between 1 to 28 days to complete and may include more than one study visit in order to complete the various procedures.
Before any study-related procedures that are not standard of care are performed, you will be asked to read the information sheet and sign a consent form. It is your right as a participant to have the study fully explained to you and you can ask your study doctor to explain or go over any parts of this information, or the consent form, that you do not understand.
Please read the Participant Information Sheet for full explanation.